Decode Health, founded in 2019, is a burgeoning precision medicine R&D company headquartered in Nashville, TN. Its core competency lies in delivering commercially structured findings swiftly, leveraging an automated analytical engine, proprietary patient data, and extensive scientific expertise. This distinctive approach eschews reliance on self-service tools and traditional, non-compounding engagements.
The company's platform encompasses two primary areas: molecular biomarker discovery and clinical decision support, operating through structured, phase-defined programs with clear deliverables and decision gates. This results in real-time evaluation for partners before deepening collaborations, creating a continuously improving, proprietary data estate.
Decode Health has garnered over $2.2M in NIH/NIAID SBIR funding, with research spanning autoimmunity, oncology, and other sectors. Its disease-agnostic framework facilitates easy expansion without rebuilding, drawing partnerships from Fortune 500 companies to academic institutions, catering primarily to pharma, diagnostics, and health tech firms seeking expedited validated findings.